Human Trials

Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial

AstraZeneca said that Imfinzi (durvalumab) has been demonstrated to have delivered a sustained overall survival (OS) benefit in the final analysis of the phase 3 CASPIAN trial in extensive-stage small cell lung cancer.

Merck announces top-line results from phase 3 trials evaluating Gefapixant

Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough.

Moderna doses first patient with mRNA-1273 in coronavirus vaccine trial

Moderna has announced the dosing of the first participant in a phase1 study of mRNA-1273, the company’s mRNA vaccine candidate against the novel coronavirus (SARS-CoV-2).

Pfizer, EMD Serono to scrap phase 3 study of avelumab in LA SCCHN

Pfizer and EMD Serono are set to scrap the phase 3 JAVELIN Head and Neck 100 study as it was found that avelumab in addition to chemoradiotherapy (CRT) is unlikely to deliver the desired result.

FDA clears first clinical study for a polymicrobial phage library-based treatment for antibiotic-resistant infections

Adaptive Phage Therapeutics (APT) said that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of PhageBank, a personalized bacteriophage therapeutic for the treatment of MDR and complicated bacterial infections.

TOURMALINE-MM2 study on NINLARO fails to deliver desired results

Takeda Pharmaceutical said that the phase 3 TOURMALINE-MM2 study evaluating the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in certain multiple myeloma population could not deliver the desired results.

InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects

InMed Pharmaceuticals has completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).

Kala’s dry eye disease candidate KPI-121 meets objective in STRIDE 3 trial

Kala Pharmaceuticals said that its dry eye disease candidate KPI-121 0.25% has delivered positive results in a phase 3 trial called STRIDE 3.

BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the first patients have been dosed with BCX9930 in a proof of concept trial in paroxysmal nocturnal hemoglobinuria (PNH). These patients were naïve to eculizumab and ravulizumab.